Wall Street analysts expect Nabriva Therapeutics PLC – (NASDAQ:NBRV) to post $2.60 million in sales for the current fiscal quarter, according to Zacks Investment Research. Four analysts have made estimates for Nabriva Therapeutics’ earnings. The highest sales estimate is $7.07 million and the lowest is $600,000.00. Nabriva Therapeutics reported sales of $970,000.00 during the same quarter last year, which indicates a positive year over year growth rate of 168%. The company is scheduled to announce its next quarterly earnings results on Thursday, November 8th.

On average, analysts expect that Nabriva Therapeutics will report full year sales of $11.84 million for the current financial year, with estimates ranging from $9.45 million to $16.32 million. For the next fiscal year, analysts forecast that the company will post sales of $13.84 million per share, with estimates ranging from $7.00 million to $18.75 million. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side analysts that cover Nabriva Therapeutics.

Nabriva Therapeutics (NASDAQ:NBRV) last posted its quarterly earnings results on Thursday, August 9th. The biotechnology company reported ($0.44) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.48) by $0.04. Nabriva Therapeutics had a negative net margin of 642.38% and a negative return on equity of 77.40%. The business had revenue of $0.85 million during the quarter, compared to the consensus estimate of $1.16 million.

Several research firms recently issued reports on NBRV. Zacks Investment Research raised shares of Nabriva Therapeutics from a “hold” rating to a “buy” rating and set a $3.00 price target for the company in a research report on Wednesday, August 1st. ValuEngine raised shares of Nabriva Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, May 2nd. Northland Securities initiated coverage on Nabriva Therapeutics in a research note on Thursday, May 31st. They set an “outperform” rating on the stock. Cantor Fitzgerald set a $16.00 price objective on Nabriva Therapeutics and gave the company a “buy” rating in a research note on Tuesday, May 8th. Finally, Needham & Company LLC set a $18.00 price objective on Nabriva Therapeutics and gave the company a “buy” rating in a research note on Thursday, August 9th. One investment analyst has rated the stock with a hold rating and ten have assigned a buy rating to the company’s stock. Nabriva Therapeutics currently has an average rating of “Buy” and a consensus target price of $16.11.

NASDAQ NBRV traded up $0.02 during mid-day trading on Friday, hitting $2.58. The company’s stock had a trading volume of 224,700 shares, compared to its average volume of 423,702. Nabriva Therapeutics has a twelve month low of $2.33 and a twelve month high of $14.10. The company has a current ratio of 7.52, a quick ratio of 7.52 and a debt-to-equity ratio of 0.01. The company has a market cap of $1.77 billion, a P/E ratio of -1.02 and a beta of 1.55.

In related news, Director Stephen W. Webster acquired 8,000 shares of the company’s stock in a transaction on Wednesday, May 23rd. The shares were acquired at an average cost of $4.59 per share, for a total transaction of $36,720.00. Following the purchase, the director now owns 8,000 shares in the company, valued at $36,720. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Daniel D. Burgess acquired 36,000 shares of the company’s stock in a transaction on Tuesday, July 31st. The shares were bought at an average price of $2.75 per share, for a total transaction of $99,000.00. Following the completion of the purchase, the director now owns 36,000 shares in the company, valued at approximately $99,000. The disclosure for this purchase can be found here. Over the last 90 days, insiders have acquired 68,660 shares of company stock worth $238,711. Company insiders own 2.79% of the company’s stock.

Large investors have recently modified their holdings of the business. Trexquant Investment LP bought a new stake in shares of Nabriva Therapeutics during the 1st quarter worth $244,000. Goldman Sachs Group Inc. bought a new stake in shares of Nabriva Therapeutics during the 4th quarter worth $637,000. Wedbush Securities Inc. bought a new stake in shares of Nabriva Therapeutics during the 2nd quarter worth $371,000. Millennium Management LLC bought a new stake in shares of Nabriva Therapeutics during the 4th quarter worth $5,188,000. Finally, BlackRock Inc. bought a new stake in shares of Nabriva Therapeutics during the 4th quarter worth $1,067,000. Institutional investors and hedge funds own 52.53% of the company’s stock.

Nabriva Therapeutics Company Profile

Nabriva Therapeutics plc, a clinical stage biopharmaceutical company, engages in the research and development of anti-infective agents to treat infections in humans. The company focuses on the pleuromutilin class of antibiotics. Its lead product candidate is lefamulin, which is in Phase III clinical trials in intravenous and oral formulations for the treatment of community-acquired bacterial pneumonia; and has completed Phase II clinical trials for the treatment of acute bacterial skin and skin structure infection.

Featured Article: How to Invest in Growth Stocks

Get a free copy of the Zacks research report on Nabriva Therapeutics (NBRV)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Nabriva Therapeutics (NASDAQ:NBRV)

Receive News & Ratings for Nabriva Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.